Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIOMARIN PHARMACEUTICAL INC.

(BMRN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Falling This Afternoon

09/07/2021 | 03:55pm EDT


© MT Newswires 2021
All news about BIOMARIN PHARMACEUTICAL INC.
10/12BIOMARIN TO HOST THIRD QUARTER 2021 : 30pm ET
PR
10/04BIOMARIN PHARMACEUTICAL : Hires Industry Veterans to Fill Key Roles in R&D and Technical O..
PR
10/04BioMarin Pharmaceutical Inc. Hires Harold S. Bernstein as Chief Medical Officer and Hea..
CI
09/20SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioMa..
PR
09/09SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioMa..
PR
09/09WALL STREET STOCK EXCHANGE : A step closer to tapering
09/09ANALYST RECOMMENDATIONS : Boohoo, Boston Beer, Cisco Systems, Eversource, Frontline...
09/09BIOMARIN PHARMACEUTICAL : Stifel Upgrades BioMarin Pharmaceutical to Buy from Hold, Adjust..
MT
09/07Health Care Down As Rally In Sector Pauses -- Health Care Roundup
DJ
09/07PPG Industries, BioMarin fall; AMC, Callaway Golf rise
AQ
More news
Analyst Recommendations on BIOMARIN PHARMACEUTICAL INC.
More recommendations
Financials (USD)
Sales 2021 1 852 M - -
Net income 2021 -88,2 M - -
Net cash 2021 262 M - -
P/E ratio 2021 -155x
Yield 2021 -
Capitalization 13 520 M 13 520 M -
EV / Sales 2021 7,16x
EV / Sales 2022 6,06x
Nbr of Employees 3 059
Free-Float 99,4%
Chart BIOMARIN PHARMACEUTICAL INC.
Duration : Period :
BioMarin Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOMARIN PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Last Close Price 73,74 $
Average target price 110,65 $
Spread / Average Target 50,1%
EPS Revisions
Managers and Directors
Jean-Jacques Bienaimé Chairman & Chief Executive Officer
Brian R. Mueller Chief Financial Officer & Executive Vice President
Henry J. Fuchs President-Worldwide Research & Development
Eduardo E. Von Pervieux Chief Information Officer
Lon Cardon Chief Scientific Strategy Officer & Senior VP
Sector and Competitors
1st jan.Capi. (M$)
BIOMARIN PHARMACEUTICAL INC.-15.91%13 520
CSL LIMITED4.48%100 550
WUXI BIOLOGICS (CAYMAN) INC.10.21%61 723
SAMSUNG BIOLOGICS CO.,LTD.6.54%48 773
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.10.35%40 270